EAM
MLTX icon

Exos Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Exos Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,100
Closed -$250K – 368
2021
Q3 		$250K Hold
25,100
– – 0.13% 185
2021
Q2 		$260K Buy
25,100
+20,100
+402% +$204K 0.14% 232
2021
Q1 		$51K Hold
5,000
– – 0.04% 295
2020
Q4 		$57K Buy
+5,000
New +$53.1K 0.09% 160

Other funds holding MLTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Exos Asset Management's MLTX Position: Q4 2021 in Review

Exos Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2021, closing a stake of 25,100 shares — an estimated $250K sold.

Exos Asset Management first reported a position in MLTX in Q4 2020 and held it in 4 quarters. The position peaked at $260K in Q2 2021. 45 funds tracked by Wall St. Rank hold MLTX as of Q4 2021.

  • Exos Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Exos Asset Management sold 25,100 MoonLake Immunotherapeutics shares in Q4 2021, an estimated $250K.
  • Exos Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 4 quarters.
  • Exos Asset Management's MoonLake Immunotherapeutics position peaked at $260K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2021.

Based on Exos Asset Management's 13F filing for Q4 2021, filed 14 Mar 2022.